A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Inclusion Criteria:

Age:

• Males and females ≥18 years of age at the time of consent

Type of Participant and Disease Characteristics:

• Participant must have documented diagnosis of MM per IMWG diagnostic criteria

• ECOG performance status of 0 or 1.

• Adequate organ and bone marrow function.

For NDMM participants:

• Participants on Module 1: Newly diagnosed multiple myeloma (NDMM) without prioranti- myeloma therapy (no more than 2 cycles of induction therapy before enrollmentare acceptable)

• For participants on Module 2: Newly diagnosed MM with a minimum of 4 cycles and amaximum of 6 cycles of induction therapy completed prior to screening

• Classified as high-risk MM

For Early Relapsed or Primary Refractory MM (1 or 2 prior lines of therapy) participants:

• Have received and failed 1 or 2 lines of anti-myeloma therapy

• Have received a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) as partof their previous therapy

• Have documented evidence of progressive disease based on investigator'sdetermination of response by the IMWG criteria within 1 year of starting treatment,or on or within 6 months of completing treatment of the subject's last line ofanti-myeloma therapy, or have confirmed progressive disease within 6 months prior toscreening and who are subsequently determined to be refractory or non-responsive totheir most recent anti-myeloma treatment regimen

General Exclusion Criteria:

• Have received prior treatment with CAR T therapy directed at any target

• Known active, or prior history of central nervous system (CNS) involvement orexhibits clinical signs of meningeal involvement of multiple myeloma

• Active or history of plasma cell leukemia at the time of screening

• Seropositive for human immunodeficiency virus (HIV)

• Active Hepatitis B infection

• Active Hepatitis C infection

• Serious underlying medical condition